Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Fabrizio De Benedetti, Alexei A Grom, Paul Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Pierre Quartier, Jordi Antón, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Cristina de Min

Blood (2021) 138 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2021-147596

Published: 2021

Journal Articles

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Alexei A Grom, Jeanette Bachir, Veronica Asnaghi, Fabrizio De Benedetti

Blood (2021) 138 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2021-146770

Published: 2021

Journal Articles

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli, Michael B. Jordan, MD, Carl E. Allen, MDPhD, Simone Cesaro, MD, Carmelo Rizzari, MD, Anupama Rao, MD, Barbara Degar, MD, Timothy Garrington, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena, MD, Alexei A. Grom, MD, Fabrizio De Benedetti, MD, Walter Giovanni Ferlin, PhD, Maria Ballabio, MD, Cristina De Min, MD

Blood (2018) 132 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood-2018-120810

Published: 2018

Journal Articles

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

Eric S. Weiss, Charlotte Girard-Guyonvarc’h, Dirk Holzinger, Adriana A. de Jesus, Zeshan Tariq, Jennifer Picarsic, Eduardo J. Schiffrin, Dirk Foell, Alexei A. Grom, Sandra Ammann, Stephan Ehl, Tomoaki Hoshino, Raphaela Goldbach-Mansky, Cem Gabay, Scott W. Canna

Blood (2018) 131 (13): 1442–1455.

https://doi.org/10.1182/blood-2017-12-820852

Published: 2018

Includes: Supplemental data

Journal Articles

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Michael Jordan, MD, Franco Locatelli Prof, MD, PhD, Carl Allen, MD, PhD, Fabrizio De Benedetti, MD, PhD, Alexei A. Grom, Maria Ballabio, MD, Walter Giovanni Ferlin, PhD, NI-0501-04 Study Group, Cristina De Min, MD

Blood (2015) 126 (23): LBA-3.

https://doi.org/10.1182/blood.V126.23.LBA-3.LBA-3

Published: 2015

Journal Articles

Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis

Janos Sumegi, Shawnagay V. Nestheide, Michael G. Barnes, Joyce Villanueva, Kejian Zhang, Alexei A. Grom, Alexandra H. Filipovich

Blood (2013) 121 (7): e14–e24.

https://doi.org/10.1182/blood-2012-05-425769

Published: 2013

Includes: Supplemental data

Journal Articles

Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis

Janos Sumegi, Michael G. Barnes, Shawnagay V. Nestheide, Susan Molleran-Lee, Joyce Villanueva, Kejian Zhang, Kimberly A. Risma, Alexei A. Grom, Alexandra H. Filipovich

Blood (2011) 117 (15): e151–e160.

https://doi.org/10.1182/blood-2010-08-300046

Published: 2011

Includes: Supplemental data

NARROW

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis

Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis

Email alerts

ASH Publications

American Society of Hematology

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis

Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only